证券代码：002817 证券简称：黄山胶囊 公告编号：2023-016 安徽黄山胶囊股份有限公司 关于举办2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、业绩说明会内容 安徽黄山胶囊股份有限公司（以下简称"公司"）已于2023年4月28日在巨 潮资讯网（http://www.cninfo.com.cn/）上披露了《黄山胶囊2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，加强公司与投资者的沟 通互动，定于2023年05月10日（星期三）下午15:00至17:00时在"黄山胶囊投资 者关系"小程序举行2022年度网上业绩说明会。 二、投资者参会方式 本次年度业绩说明会将通过约调研平台采用网络远程方式举行，投资者可通 过以下方式参与本次业绩说明会： 参与方式一：在微信小程序中搜索"黄山胶囊投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"黄山胶囊投资者关系"小程序，即可参与交流。 三、参会人员 出席本次网上说明会的人员有：董事、总经理余超彪先生，独立董事沙风先 生，副总 ...

证券代码：002817 证券简称：黄山胶囊 安徽黄山胶囊股份有限公司投资者关系活动记录表 编号：2019-001 | --- | --- | --- | |-------------------------|-----------------------------|------------------------------------------------------| | | □ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 ■业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 人员姓名 | 投资者 | | | | | | | 时间 | 2019 年 5 月 6 日 | 15:00-17:00 | | 地点 | " 全景•路演天下"（ | http://rs.p5w.net ） | | 上市公司接待人 | 董事长 余春明 | | | 员姓名 | 总经理 余超彪 | | | | 董事会秘书 项先理 | | | | 财务负责人 汪红时 | | | | 独立董事 曲凯 | | | | 保荐代表人 高震 | ...

Group 1: Company Overview and Strategy - Anhui Huangshan Capsule Co., Ltd. aims to become a leading pharmaceutical technology service platform in China [1][4] - The company focuses on scientific budgeting and refined management to align expenses with business development [4] Group 2: Product Information - The main product, gelatin hollow capsules, is primarily used for drugs sensitive to light and moisture, enhancing bioavailability compared to tablets [5] - The market for gelatin hollow capsules remains dominant, with HPMC plant-based capsules as a supplementary option due to higher costs and regulatory restrictions [4][5] Group 3: Financial Performance and Market Position - The company reported a significant portion of revenue from gelatin hollow capsules, indicating a concentrated revenue stream [6][7] - The company has established a good reputation among domestic pharmaceutical and health food enterprises, maintaining a stable customer base [7] Group 4: Overseas Market Expansion - The company has made progress in expanding into the North American market, including the establishment of a subsidiary in the U.S. and exporting five batches of capsules [7][9] - Future overseas sales are expected to grow, driven by increased demand due to the COVID-19 pandemic [9][13] Group 5: Risks and Challenges - Potential risks in overseas expansion include rising shipping costs, exchange rate fluctuations, and instability in overseas client operations due to the pandemic [6][13] - The company is aware of the challenges posed by the international political environment and is prepared to address them [13] Group 6: Research and Development - The company plans to increase investment in R&D, focusing on plant-based capsules and enteric-coated gelatin capsules to diversify its product offerings [8][10] - Current production capacity is projected to exceed 40 billion capsules, supported by the completion of a digital workshop [11]

Group 1: Financial Performance and Investment - The company has seen a 43.76% increase in R&D investment in 2021 compared to the previous year, reflecting its ongoing commitment to research and development [1][2] - The company has not engaged in direct financing since its IPO, relying instead on loans for specific projects, such as the "Hollow Capsule Intelligent Manufacturing New Model" project [1] - The company maintains a low level of interest-bearing debt, benefiting from favorable bank loan rates [1] Group 2: Production Capacity and Market Position - Anhui Huangshan Capsule Co., Ltd. is one of the largest manufacturers of pharmaceutical hollow capsules, with an annual production capacity exceeding 40 billion capsules [2] - The company utilizes advanced intelligent manufacturing technology, allowing for the production of various specifications and customized services [2] Group 3: Shareholder Concerns and Market Performance - The company's stock price has declined significantly from a peak of 83 yuan to below 8 yuan, raising concerns among shareholders about the company's future [2] - The company is focused on steady operations and aims to create sustainable long-term returns for investors despite market fluctuations [2]

Financial Performance - The company's revenue for Q3 2022 was ¥93,656,298.81, representing a 13.10% increase year-over-year[5] - Net profit attributable to shareholders for the same period was ¥16,583,398.01, up by 3.32% compared to the previous year[5] - Total operating revenue for the third quarter of 2022 was CNY 301,178,173.56, an increase of 8.3% compared to CNY 278,105,057.36 in the same period last year[39] - Net profit for the third quarter reached CNY 48,220,190.73, representing a 16.5% increase from CNY 41,406,384.94 in the previous year[40] - Earnings per share (EPS) for the quarter was CNY 0.16, compared to CNY 0.14 in the same quarter last year, indicating a growth of 14.3%[40] - The total equity attributable to shareholders of the parent company was CNY 840,944,224.34, up from CNY 809,694,572.19, reflecting a growth of 3.9%[39] - The total comprehensive income for the quarter was CNY 48,522,337.05, an increase from CNY 41,496,818.78, representing a growth of 17.3%[40] Cash Flow - The operating cash flow net amount for the year-to-date period reached ¥67,058,100.52, showing a significant increase of 111.46%[5] - The net cash flow from operating activities increased by ¥35,345,400, a growth of 111.46%, attributed to higher cash receipts from sales[29] - The net cash flow from operating activities for the period was ¥67,058,100.52, an increase of 111.1% compared to ¥31,712,693.40 in the previous period[41] - Total cash inflow from investment activities was ¥453,876,802.98, significantly higher than ¥5,458,760.93 in the previous period[41] - The net cash flow from investment activities was -¥246,780,048.91, worsening from -¥63,490,876.00 in the previous period[41] - Cash flow from financing activities resulted in a net outflow of -¥22,234,805.05, compared to a net inflow of ¥39,251,572.00 in the previous period[42] - The total cash and cash equivalents at the end of the period stood at ¥142,238,131.71, down from ¥248,958,363.80 at the end of the previous period[42] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,093,508,453.78, reflecting a 3.77% increase from the end of the previous year[5] - The total liabilities increased to CNY 252,101,974.12 from CNY 243,844,826.99, marking a rise of 3.1%[39] - The company’s non-current liabilities decreased to CNY 93,153,737.79 from CNY 97,947,796.63, a decline of 5.0%[39] - The company’s non-current assets total RMB 422,465,387.55 as of September 30, 2022, slightly up from RMB 414,167,687.10 at the beginning of the year[36] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,622[31] - The largest shareholder, Yu Chunming, holds 38.05% of shares, totaling 113,802,815 shares, with 37,020,000 shares pledged[31] Investments and Expenses - The company reported a 116.08% increase in trading financial assets, amounting to ¥75,617,300, primarily due to investments in bank wealth management products[9] - Research and development expenses for the quarter were CNY 10,418,005.92, slightly down from CNY 11,284,663.73, indicating a decrease of 7.7%[39] - The company reported a financial income of CNY 4,837,532.59, compared to CNY 5,366,642.46 in the previous year, showing a decline of 9.9%[39] Inventory and Receivables - The company’s inventory as of September 30, 2022, is RMB 115,712,327.43, up from RMB 90,742,292.83 at the beginning of the year[36] - The company reported accounts receivable of RMB 103,197,011.65 as of September 30, 2022, an increase from RMB 80,999,747.90 at the beginning of the year[36]

Group 1: Event Details - Anhui Huangshan Capsule Co., Ltd. will participate in the "2022 Anhui Listed Companies Investor Collective Reception Day" [2] - The event will be held online on September 7, 2022, from 16:00 to 17:30 [2] - Investors can join via the "Panorama Roadshow" website, WeChat public account, or the Panorama Roadshow APP [2] Group 2: Communication Objectives - Company executives will discuss the 2022 semi-annual report, including company performance, governance, development strategy, operational status, and sustainable development [2] - The event aims to enhance interaction and communication with investors [2] Group 3: Assurance of Information - The company and its board guarantee the announcement's content is true, accurate, and complete, with no false records or significant omissions [2]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥207,521,874.75, representing a 6.26% increase compared to ¥195,297,816.23 in the same period last year[22]. - The net profit attributable to shareholders was ¥31,515,861.09, an increase of 18.22% from ¥26,657,994.57 in the previous year[22]. - Basic and diluted earnings per share increased by 22.22% to ¥0.11, compared to ¥0.09 in the previous year[22]. - The company achieved a revenue of 207.52 million yuan in the first half of 2022, an increase of 6.26% compared to the same period last year[34]. - The net profit attributable to shareholders was 31.52 million yuan, up 18.22% year-on-year[34]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 24.27 million yuan, an increase of 7.98% year-on-year[34]. - The gross profit margin for the reporting period was impacted by increased costs, with operating cash flow decreasing by 24.11% to ¥23,293,267.85[45]. - The company's revenue for the pharmaceutical hollow capsule manufacturing industry reached ¥207.52 million, an increase of 6.26% compared to the same period last year, while the gross margin decreased by 2.03% to 27.75%[49]. - The net profit for the first half of 2022 was CNY 31,474,542.80, up from CNY 25,670,833.48 in the previous year, indicating a growth of approximately 22.5%[126]. - The total comprehensive income for the first half of 2022 was CNY 31,481,808.87, showing a significant increase compared to the previous year[144]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 24.11% to ¥23,293,267.85, down from ¥30,694,740.20 in the same period last year[22]. - The company faced a decrease in cash flow from operating activities, indicating potential challenges in maintaining liquidity[22]. - Cash and cash equivalents decreased by 16.14% to ¥176.88 million, representing 16.53% of total assets, down from 32.67%[50]. - The cash flow from operating activities generated a net amount of CNY 23,293,267.85, down from CNY 30,694,740.20 in the first half of 2021, indicating a decrease of 24.2%[132]. - The company reported a decrease in cash flow from financing activities, with a net outflow of CNY 19,923,044.79 compared to a net inflow of CNY 39,668,892.33 in the first half of 2021[134]. - The cash flow from investment activities was not detailed, but the overall cash position indicates challenges in liquidity management[136]. Market and Product Development - The company focuses on the research, production, and sales of gelatin hollow capsules and enteric-coated gelatin hollow capsules, which are essential for packaging sensitive pharmaceuticals[32]. - The company is actively expanding its market presence, particularly in the traditional Chinese medicine sector, to ensure continuous sales growth[33]. - The company is investing in technological upgrades and diversifying its product offerings to capture more market share[33]. - The company has established a robust marketing network, serving over 30 provinces and regions across China, enhancing its industry recognition[36]. - The company plans to launch two new products in Q3 2022, aiming to capture a larger segment of the market[92]. - The company is focusing on strategic acquisitions to enhance its competitive position in the market[93]. - The company plans to continue its market expansion strategy, focusing on increasing its production capacity and enhancing product offerings[94]. Risk Management - The company has outlined risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks from regulatory changes in the pharmaceutical industry, which could impact market competition and product quality[58]. - Rising prices of raw materials, particularly gelatin for capsules, pose a risk to the company's cost structure and profit margins[58]. - The company plans to enhance its product structure and market expansion efforts to mitigate risks associated with price competition in the pharmaceutical sector[58]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has established a profit distribution policy and a three-year shareholder return plan to ensure reasonable returns for shareholders[68]. - The company reported a profit distribution of CNY 17,091,324.00 to shareholders, indicating a commitment to returning value to investors[145]. - The total equity attributable to shareholders at the end of the reporting period was 765.1 million yuan, showing a slight increase from the previous period[141]. Research and Development - Research and development investment rose by 4.12% to ¥7,269,786.64, up from ¥6,982,110.93, reflecting the company's commitment to innovation[45]. - The company is focusing on research and development of new technologies to drive future growth and innovation[145]. - New product development initiatives are underway, with an investment of 500 million CNY allocated for R&D in innovative technologies[92]. Environmental and Regulatory Compliance - The company emphasizes environmental protection and sustainable development, aligning with national policies and regulations[69]. - The company strictly adheres to laws and regulations, ensuring timely and accurate information disclosure to protect the rights of shareholders and creditors[68]. - The company has not faced any significant legal disputes or administrative penalties during the reporting period[79]. Financial Management and Accounting - The company adheres to the enterprise accounting standards, ensuring that its financial statements accurately reflect its financial position and operating results[153]. - The company has established specific accounting policies and estimates for financial instruments, fixed asset depreciation, and revenue recognition[152]. - Financial instruments are subject to impairment measurement based on expected credit losses, with loss provisions recognized for various financial assets[178].

Financial Performance - The company's revenue for Q1 2022 was ¥101,310,277.27, a decrease of 2.68% compared to ¥104,095,453.39 in the same period last year[3] - Net profit attributable to shareholders increased by 29.36% to ¥13,969,880.23 from ¥10,799,475.10 year-on-year[3] - Net profit for Q1 2022 reached ¥13,929,428.55, representing an increase of 36.5% from ¥10,244,482.70 in Q1 2021[18] - The total comprehensive income for the parent company attributable to owners was CNY 13,960,700.25, compared to CNY 10,813,442.19 in the previous period, reflecting an increase of approximately 28.5%[19] Cash Flow - The net cash flow from operating activities rose by 59.19% to ¥23,600,068.31, compared to ¥14,824,838.69 in the previous year[3] - The cash inflow from operating activities totaled CNY 73,910,120.63, while cash outflow was CNY 50,310,052.32, resulting in a net cash flow of CNY 23,600,068.31[21] - The net cash flow generated from operating activities was CNY 23,600,068.31, up from CNY 14,824,838.69 in the previous period, indicating a growth of about 59.8%[21] - The net increase in cash and cash equivalents decreased by 2405.69% to a net decrease of ¥11,378.32 million, primarily due to reduced cash flows from investing and financing activities[8] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,084,560,420.74, reflecting a 2.92% increase from ¥1,053,820,293.60 at the end of the previous year[3] - Total assets as of the end of Q1 2022 were ¥1,084,560,420.74, an increase from ¥1,053,820,293.60 at the beginning of the year[14] - Total liabilities increased to ¥260,667,000.55 from ¥243,844,826.99 at the beginning of the year, reflecting a rise of 6.9%[15] Earnings and Profitability - Basic earnings per share increased by 40.00% to ¥0.07 from ¥0.05 in the same period last year[3] - Basic and diluted earnings per share were both CNY 0.07, an increase from CNY 0.05 in the previous period, representing a growth of 40%[19] - The company reported a gross profit margin of approximately 12.3% for Q1 2022, compared to 10.5% in the same period last year[18] Investment and Expenditures - The company reported a significant increase in trading financial assets, which rose by 193.17% to ¥12,583.14 million due to investments in bank wealth management products[6] - The company incurred a cash outflow of CNY 236,249,003.97 for investment activities, compared to CNY 39,326,110.73 in the previous period, reflecting a strategic increase in capital expenditures[23] - The company reported a net cash outflow from investing activities of CNY -130,754,044.31, compared to CNY -36,398,597.41 in the previous period, showing a significant increase in investment expenditures[23] - The total cash inflow from investment activities was CNY 105,494,959.66, significantly higher than CNY 2,927,513.32 in the previous period, indicating a substantial increase in investment returns[22] Operational Efficiency - The company's government subsidies recognized in the current period amounted to ¥3,613,420.79, contributing to the increase in other income[5] - The company experienced a 30.91% increase in accounts receivable, totaling an increase of ¥2,503.32 million, indicating delayed collection of receivables[6] - Accounts receivable increased to ¥106,032,972.69, up 30.5% from ¥80,999,747.90 at the beginning of the year[13] - Research and development expenses for Q1 2022 were ¥3,869,928.41, compared to ¥3,602,953.61 in Q1 2021, indicating an increase of 7.4%[18] Future Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[18]

Financial Performance - The company's operating revenue for 2021 was CNY 379,891,008.70, representing an increase of 18.93% compared to CNY 319,426,287.89 in 2020[18]. - The net profit attributable to shareholders for 2021 was CNY 56,887,811.36, up 25.70% from CNY 45,255,710.15 in the previous year[18]. - The net profit after deducting non-recurring gains and losses was CNY 48,301,265.66, reflecting a growth of 32.54% from CNY 36,442,844.58 in 2020[18]. - The net cash flow from operating activities increased by 37.28% to CNY 86,089,406.99, compared to CNY 62,711,557.61 in 2020[18]. - The total assets at the end of 2021 reached CNY 1,053,820,293.60, a 15.07% increase from CNY 915,812,091.29 at the end of 2020[18]. - The net assets attributable to shareholders were CNY 809,694,572.19, which is a 6.30% increase from CNY 761,707,349.51 in 2020[18]. - The basic earnings per share for 2021 were CNY 0.27, up 28.57% from CNY 0.21 in the previous year[18]. - The weighted average return on equity for 2021 was 7.25%, an increase from 6.10% in 2020[18]. Cash Flow and Investments - The net cash flow from operating activities improved by 37.28% to ¥86,089,406.99[60]. - The net cash flow generated from financing activities increased by CNY 36.76 million, a growth rate of 334.32%, primarily due to an increase in borrowings[61]. - The net increase in cash and cash equivalents was CNY 102.40 million, a rise of 195.87%, attributed to the increase in net cash flow from operating and financing activities[61]. - As of the end of 2021, cash and cash equivalents amounted to CNY 344.29 million, representing 32.67% of total assets, up from 26.43% at the beginning of the year[63]. - The company invested CNY 13.44 million in R&D, completing 9 technical innovations and filing 7 invention patents during the reporting period[44]. Market and Sales Performance - Domestic sales accounted for 96.90% of total revenue, while international sales surged by 360.62% to CNY 11.79 million[47]. - The company’s gelatin hollow capsules generated CNY 312.63 million in revenue, representing 82.29% of total sales, with a year-on-year growth of 20.59%[47]. - The sales volume of gelatin hollow capsules increased by 19.84% to 2,834,163.14 million units, while production volume rose by 30.81%[50]. - The company is actively expanding its market presence and strengthening cooperation with clients in the chemical drug procurement sector[34]. Research and Development - The company is committed to increasing R&D investment to enhance its competitive edge in the pharmaceutical technology service sector[41]. - The total number of R&D personnel increased by 18.06% to 85, enhancing the company's innovation capacity[58]. - The company has developed core technologies in enteric coating materials and hollow capsule production, securing several patents and industry recognitions[40]. Governance and Management - The company’s governance structure is in accordance with the requirements set by the China Securities Regulatory Commission, with independent operations of the board of directors and supervisory board[80]. - The company has established an independent financial department and accounting system, ensuring autonomous financial decision-making and compliance with tax obligations[86]. - The company has appointed independent directors with extensive backgrounds in finance and pharmaceuticals, enhancing governance[96]. - The company has a diverse board with members having backgrounds in engineering, economics, and pharmaceuticals, which supports its strategic direction[95]. Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of CNY 0.80 per 10 shares, with a capital reserve conversion of 4 shares for every 10 shares held[4]. - The company implemented a cash dividend policy, distributing a total of 17,091,324.00 CNY, which represents 30.04% of the total profit distribution[118]. - The company’s profit distribution policy emphasizes reasonable, continuous, and stable returns to shareholders while considering long-term interests[116]. Risks and Challenges - The company faces risks related to regulatory changes in the pharmaceutical industry and fluctuations in raw material prices, particularly for gelatin used in capsules[75]. - The pharmaceutical industry is facing significant risks of product price reductions due to policies such as consistency evaluation of generic drugs and national volume-based procurement, leading to a decline in gross margins and increased competition[76]. Internal Controls and Compliance - The company reported no major or important internal control deficiencies during the reporting period, indicating effective internal control systems[122][124]. - The company has established a comprehensive internal control system that complies with relevant regulations and has been effectively implemented[122]. - The company maintained a continuous relationship with Tianjian Accounting Firm for 13 years, with an audit fee of 500,000 RMB for the current period[142]. Social Responsibility - The company actively engages in social responsibility initiatives, donating RMB 154,000 to charitable causes during the reporting period[131]. - The company has invested in environmental protection technologies, including a supercritical carbon dioxide system and a catalytic combustion system, to reduce emissions and energy consumption[131].

Revenue and Profit - Revenue for Q3 2021 reached ¥82,807,241.13, an increase of 14.96% year-over-year, while year-to-date revenue was ¥278,105,057.36, up 29.28% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥16,051,184.94, reflecting an 11.98% increase year-over-year, with year-to-date net profit at ¥42,709,179.51, up 27.03%[3] - The net profit for the third quarter of 2021 was CNY 41,406,384.94, an increase of 27.4% compared to CNY 32,497,215.85 in the same period last year[18] - The total comprehensive income for the third quarter was CNY 41,496,818.78, up from CNY 32,497,215.85, reflecting a growth of 27.7%[18] - Operating profit for the period was RMB 46,105,482.36, an increase of 20.5% from RMB 38,282,503.48 in the previous year[16] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥0.08, a 14.29% increase compared to the same period last year, while year-to-date earnings per share was ¥0.20, up 25.00%[3] - Basic earnings per share for the quarter were CNY 0.20, compared to CNY 0.16 in the previous year, representing a 25% increase[19] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥981,243,823.86, representing a 7.14% increase from the end of the previous year[3] - The company's total assets as of September 30, 2021, were RMB 981,243,823.86, compared to RMB 915,812,091.29 at the end of 2020, reflecting a growth of 7.1%[14] - The company's total liabilities increased to RMB 183,237,603.32, compared to RMB 150,662,349.53 at the end of 2020, marking a rise of 21.6%[15] - The equity attributable to shareholders of the parent company reached RMB 795,668,518.91, up from RMB 761,707,349.51, reflecting a growth of 4.5%[15] Cash Flow - Cash flow from operating activities for the year-to-date period decreased by 5.03% to ¥31,712,693.40[3] - Cash flow from operating activities generated a net cash inflow of CNY 31,712,693.40, slightly down from CNY 33,391,452.32 in the previous year[21] - Cash and cash equivalents stood at RMB 249,503,797.18, showing an increase from RMB 242,007,755.38 at the end of 2020[13] - Total cash and cash equivalents at the end of the period amounted to CNY 248,958,363.80, an increase from CNY 234,888,104.96 at the end of the previous year[22] - Cash inflows from operating activities totaling CNY 233,627,129.34, compared to CNY 176,154,017.30 in the same period last year, marking a growth of 32.6%[21] - Cash outflows from operating activities were CNY 201,914,435.94, up from CNY 142,762,564.98, indicating a 41.4% increase[21] - Investment activities resulted in a net cash outflow of CNY 63,490,876.00, compared to a net outflow of CNY 213,104.06 in the previous year[22] - Financing activities generated a net cash inflow of CNY 39,251,572.00, reversing from a net outflow of CNY 5,162,183.38 in the same period last year[22] Research and Development - Research and development expenses increased by ¥4,945,300, a growth of 78.01% year-over-year, indicating increased investment in R&D[8] - Research and development expenses increased significantly to RMB 11,284,663.73, a rise of 77.5% compared to RMB 6,339,384.34 in the previous year[16] Inventory and Borrowings - The company experienced a 51.57% increase in inventory, amounting to an increase of ¥36,618,900, primarily due to increased stockpiling[7] - Inventory levels rose to RMB 107,628,406.18, up from RMB 71,009,457.51, indicating a 51.5% increase year-on-year[14] - The company reported a significant increase in long-term borrowings, which rose by ¥47,542,800, a growth of 342.92% compared to the beginning of the year[7] Return on Equity - The company’s weighted average return on equity was 2.04% for Q3 2021, reflecting a 5.70% increase compared to the same period last year[3]